During his tenure at BioMarin, Bienaimé steered BioMarin from ... “With nearly three decades experience as CEO, Mr Bienaimé’s proven track record and visionary leadership will inspire ...

Earnings Call Insights: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue ...

Brian Mueller, Chief Financial Officer; Cristin Hubbard, Chief Commercial Officer; and Greg Friberg, Chief R&D Officer. I will now turn the call over to BioMarin's President and CEO, Alexander Hardy.

Walbert, the former chairman, president, and CEO of Horizon Therapeutics (NASDAQ:HZNP), brings over three decades of experience in the pharmaceutical industry to BioMarin's board. According to ...

BioMarin's resources did not go unnoticed by the deal-hungry biotech community. “We had 155 meetings at J.P. Morgan,” CEO Alexander Hardy said on the company’s Feb. 19 earnings call.

BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé will retire in December, when he will be succeeded by Genentech CEO Alexander Hardy. The transition comes with BioMarin in the early stages of ...

we expect continued high performance as we benefit from BioMarin's revamped corporate strategy and operating model in 2025 and beyond," said Alexander Hardy, President and CEO of BioMarin.

Walbert, the former chairman, president, and CEO of Horizon Therapeutics (NASDAQ:HZNP), brings over three decades of experience in the pharmaceutical industry to BioMarin's board. According to ...

I will now turn the call over to BioMarin's President and CEO, Alexander Hardy. Thank you, Traci, and good afternoon, everyone. Thank you for joining us today for our fourth quarter 2024 results ...